Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000

Wang, Shu; Malebari, Azizah M.; Greene, Thomas F.; Kandwal, Shubhangi; Fayne, Darren; Nathwani, Seema M.; Zisterer, Daniela M.; Twamley, Brendan; O’Boyle, Niamh M.; Meegan, Mary J.

doi:10.3390/ph18081218

Open AccessCorrection

Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000

by

Shu Wang

^1,†,

Azizah M. Malebari

^2,†,

Thomas F. Greene

¹,

Shubhangi Kandwal

³,

Darren Fayne

³

,

Seema M. Nathwani

⁴,

Daniela M. Zisterer

⁴

,

Brendan Twamley

⁵,

Niamh M. O’Boyle

¹

and

Mary J. Meegan

^1,*

¹

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, D02 R590 Dublin, Ireland

²

Department of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia

³

Molecular Design Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, D02 R590 Dublin, Ireland

⁴

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, D02 R590 Dublin, Ireland

⁵

School of Chemistry, Trinity College Dublin, Dublin 2, D02 PN40 Dublin, Ireland

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Pharmaceuticals 2025, 18(8), 1218; https://doi.org/10.3390/ph18081218

Submission received: 29 July 2025 / Accepted: 31 July 2025 / Published: 19 August 2025

(This article belongs to the Section Medicinal Chemistry)

Download

Browse Figure

Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 9 as published. In Figure 9, CA-4 (0.05 μM) should be corrected to CA-4 (0.01 μM). Corrected Figure 9 appears below.

Text Correction

A correction has been made to the last paragraph of Section 2.4.4. Tubulin Polymerisation Effects of 3-(Prop-1-en-2-yl)azetidinones, 3-Allylazetidinones and 3-butadienylazetidinones: “CA-4 (50 nM)” should be “CA-4 (10 nM)”.

A correction has been made to Section 3.17.8. Immunofluorescence Microscopy: “9q (50 nM, 100 nM and 500 nM)” should be “9q (10 nM, 100 nM and 500 nM)”.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

Wang, S.; Malebari, A.M.; Greene, T.F.; Kandwal, S.; Fayne, D.; Nathwani, S.M.; Zisterer, D.M.; Twamley, B.; O’Boyle, N.M.; Meegan, M.J. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. [Google Scholar] [CrossRef]

Figure 9. β-lactam compound 9q induces depolymerization of the microtubule network in MCF-7 breast cancer cells.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Wang, S.; Malebari, A.M.; Greene, T.F.; Kandwal, S.; Fayne, D.; Nathwani, S.M.; Zisterer, D.M.; Twamley, B.; O’Boyle, N.M.; Meegan, M.J. Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals 2025, 18, 1218. https://doi.org/10.3390/ph18081218

AMA Style

Wang S, Malebari AM, Greene TF, Kandwal S, Fayne D, Nathwani SM, Zisterer DM, Twamley B, O’Boyle NM, Meegan MJ. Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals. 2025; 18(8):1218. https://doi.org/10.3390/ph18081218

Chicago/Turabian Style

Wang, Shu, Azizah M. Malebari, Thomas F. Greene, Shubhangi Kandwal, Darren Fayne, Seema M. Nathwani, Daniela M. Zisterer, Brendan Twamley, Niamh M. O’Boyle, and Mary J. Meegan. 2025. "Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000" Pharmaceuticals 18, no. 8: 1218. https://doi.org/10.3390/ph18081218

APA Style

Wang, S., Malebari, A. M., Greene, T. F., Kandwal, S., Fayne, D., Nathwani, S. M., Zisterer, D. M., Twamley, B., O’Boyle, N. M., & Meegan, M. J. (2025). Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals, 18(8), 1218. https://doi.org/10.3390/ph18081218

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.

Article Menu

Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000

Error in Figure

Text Correction

Reference

Share and Cite

Article Metrics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI